Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
Inhibitors of DNA binding/inhibitors of differentiation (Id) protein family (Id-1, -2, -3 and -4) of helix-loop-helix proteins have been shown to be involved in carcinogenesis and are regarded as prognostic markers in several types of human cancers. However, the roles of Id proteins during breast carcinoma progression remain unclear. The objective was to study the effects of Id proteins in breast cancer. The expression of Id-1, Id-2, Id-3 and Id-4 proteins was examined in 122 dissected female human breast carcinoma tissues and 22 normal female breast specimens by immunohistochemical assay and the relationship between Id staining and clinical pathological characteristics of breast cancer was also analyzed. The over-expressed Id-1 and down-regulated Id-4 proteins were found both correlated with poorer differentiation and more aggressive behavior of the tumor. Id-1 protein could be termed as a negative prognostic marker while Id-4 protein as a positive marker for patients with breast carcinoma. Although the differentially expressed Id-2 and -3 may be correlated with some clinical parameters, they could not be used as independent prognostic factors in human breast cancer.
Oncology Reports – Spandidos Publications
Published: Feb 1, 2010
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.